Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study.
135 patients were entered into a 28-day randomized double-masked multicentre study comparing the efficacy and short-term safety of lodoxamide 0.1% ophthalmic solution (Alomide--Alcon Laboratories), a mast cell stabilizer, with sodium cromoglycate 2% ophthalmic solution (Opticrom--Fisons Pharmaceuticals) in the treatment of allergic eye disease. Patients given lodoxamide 0.1% showed a significantly more rapid and greater improvement in their signs and symptoms of allergic eye disease than patients given sodium cromoglycate 2%. Both treatments were found to be safe, and side-effect profiles were comparable between the two treatment groups, although the overall incidence of side-effects in this study was found to be less frequent in the lodoxamide-treated group.
Fahy
G T
GT
Bristol Eye Hospital, U.K.
Easty
D L
DL
Collum
L M
LM
Benedict-Smith
A
A
Hillery
M
M
Parsons
D G
DG
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D004205:Cromolyn Sodium / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D010072:Oxamic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D009883:Ophthalmic Solutions; D004205:Cromolyn Sodium; D010072:Oxamic Acid; C021702:lodoxamide ethyl